Neurocrine Biosciences (NBIX) News Today $123.29 +4.16 (+3.49%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Swiss National Bank Boosts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Swiss National Bank raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 298,700 shares of the company's stock after acquiring an additNovember 21 at 4:00 AM | marketbeat.comKBC Group NV Buys 8,332 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)KBC Group NV lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 78.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,972 shares of the company's stock after buying anNovember 19 at 4:10 AM | marketbeat.comVictory Capital Management Inc. Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Victory Capital Management Inc. increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 48.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 204,205 shares of the company's stock aNovember 19 at 3:49 AM | marketbeat.comEmpowered Funds LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Empowered Funds LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 681.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 62,052 shares of the company's stock after acquiring an additional 54,114 shares durNovember 17, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 11,502 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sumitomo Mitsui Trust Group Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 231,941 shares of the company'sNovember 17, 2024 | marketbeat.comImpax Asset Management Group plc Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Impax Asset Management Group plc boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 85,000 shares of the company's stock after purchasing an additional 35,00November 16, 2024 | marketbeat.comGSA Capital Partners LLP Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GSA Capital Partners LLP grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 441.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,682 shares of the company's stock after buying an additional 7,0November 16, 2024 | marketbeat.comPlato Investment Management Ltd Acquires 10,548 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Plato Investment Management Ltd increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2,481.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,973 shares of thNovember 15, 2024 | marketbeat.comAigen Investment Management LP Purchases Shares of 5,948 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Aigen Investment Management LP purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,948 shares of the company's stock, valued at approximately $685,000. Other hNovember 14, 2024 | marketbeat.comNeurocrine Biosciences Positioned for Growth Amid AbbVie’s Setback in Muscarinic ProgramNovember 13, 2024 | markets.businessinsider.comPrincipal Financial Group Inc. Has $29.17 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Principal Financial Group Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 32.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,18November 13, 2024 | marketbeat.comNeurocrine (NBIX) Receives a Buy from JefferiesNovember 12, 2024 | markets.businessinsider.comEvercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positiveNovember 11, 2024 | markets.businessinsider.comBuy Rating for Neurocrine: Strategic Advantage Amidst Reduced Competition in Muscarinic SpaceNovember 11, 2024 | markets.businessinsider.comNeurocrine Biosciences (NASDAQ:NBIX) Earns "Hold" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research report on Monday.November 11, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stake Boosted by Los Angeles Capital Management LLCLos Angeles Capital Management LLC raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 639.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ownedNovember 10, 2024 | marketbeat.comNeurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good QualityNovember 10, 2024 | finance.yahoo.comNeurocrine (NBIX) Gets a Buy from J.P. MorganNovember 9, 2024 | markets.businessinsider.comNeurocrine Biosciences: Balancing Strategic Priorities with Regulatory Challenges – Analyst Maintains Hold RatingNovember 8, 2024 | markets.businessinsider.comFiera Capital Corp Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fiera Capital Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 516,801 shares of the company's stock aftNovember 8, 2024 | marketbeat.comWhy Neurocrine Biosciences Stock Is Very Attractive At Current LevelsNovember 8, 2024 | seekingalpha.comSummit Global Investments Has $6.17 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Summit Global Investments cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 31.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 53,577 shares of thNovember 8, 2024 | marketbeat.comBeacon Harbor Wealth Advisors Inc. Takes $5.52 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Beacon Harbor Wealth Advisors Inc. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 47,917 shares of thNovember 8, 2024 | marketbeat.com31,144 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Kornitzer Capital Management Inc. KSKornitzer Capital Management Inc. KS acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 31,144 shares of the company's stock, valued at approxiNovember 8, 2024 | marketbeat.comNeurocrine's Ingrezza Shows Positive Data For Reduction Of Huntington's Disease ChoreaNovember 7, 2024 | markets.businessinsider.comNeurocrine’s Ingrezza shows efficacy in Huntington’s Disease ChoreaNovember 7, 2024 | markets.businessinsider.comNeurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNovember 7, 2024 | prnewswire.comVan ECK Associates Corp Has $9.62 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Van ECK Associates Corp decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,582 shares of the coNovember 7, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Nisa Investment Advisors LLCNisa Investment Advisors LLC lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 80.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,345 shares of the company's stock after selling 5,662 shares durNovember 7, 2024 | marketbeat.comStrong Sales and Strategic Moves Bolster Neurocrine’s Buy RatingNovember 7, 2024 | markets.businessinsider.comImpax Asset Management Group plc Has $9.79 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Impax Asset Management Group plc raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 85,000 shares of the company's stock after acquiNovember 6, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Robeco Institutional Asset Management B.V.Robeco Institutional Asset Management B.V. grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 16.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 387,282 shares of the company's stock after purchasing an aNovember 6, 2024 | marketbeat.comNeurocrine Biosciences to Participate at Investor Conferences in NovemberNovember 5, 2024 | prnewswire.comNeurocrine Says Tardive Dyskinesia Patients Saw Holistic Improvements After Ingrezza TreatmentNovember 5, 2024 | markets.businessinsider.comNeurocrine presents data from Ingrezza studies on tardive dyskines patientsNovember 5, 2024 | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Increased by AlphaCentric Advisors LLCAlphaCentric Advisors LLC grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 221.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,500 shares of the company's stock afterNovember 5, 2024 | marketbeat.comNeurocrine presents data from long-term KINECT-4 studyNovember 5, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Neurocrine (NBIX)November 5, 2024 | markets.businessinsider.comNeurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNovember 4, 2024 | prnewswire.comNeurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNovember 4, 2024 | prnewswire.comCantor Fitzgerald Has Weak Estimate for NBIX FY2024 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2024 earnings per share estimates for shares of Neurocrine Biosciences in a note issued to investors on Thursday, October 31st. Cantor Fitzgerald analyst J. Schimmer now expects thNovember 4, 2024 | marketbeat.comabrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)abrdn plc reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 15.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 136,424 shares of the company's stock after selling 24,November 2, 2024 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Buy" at StockNews.comStockNews.com downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comNeurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research note on Friday.November 1, 2024 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Mirae Asset Global Investments Co. Ltd.Mirae Asset Global Investments Co. Ltd. grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 250.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,433 shares of the company's stock after buNovember 1, 2024 | marketbeat.comStrong Performance and Promising Pipeline Drive Buy Rating for Neurocrine BiosciencesNovember 1, 2024 | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-four research firms that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rNovember 1, 2024 | marketbeat.comEvercore ISI Remains a Buy on Neurocrine (NBIX)October 31, 2024 | markets.businessinsider.comNeurocrine Tops Expectations in Q3October 31, 2024 | fool.comNeurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ...October 31, 2024 | finance.yahoo.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.610.45▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼811▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bio-Techne News Today Qiagen News Today CRISPR Therapeutics News Today Denali Therapeutics News Today Adaptive Biotechnologies News Today Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
